E3 ubiquitin ligase ASB8 promotes selinexor-induced proteasomal degradation of XPO1.

Nucleocytoplasmic transport meets CRISPR screening. We performed CRISPR screens to identify genes that affect selinexor sensitivity. We establish that our main hit, ASB8, is responsible for selinexor-induced degradation of XPO1. Additionally, we suggest that TGFβ-SMAD signaling may predict clinical benefit from selinexor treatment in patients with multiple myeloma.